In Brief: Guidant:
This article was originally published in The Gray Sheet
Guidant: Receives FDA go-ahead to market the ACS RX Comet rapid-exchange coronary dilation catheter for percutaneous transluminal coronary angioplasty (PTCA). The Comet features an "ultra-low profile and sleek design" that allows "easy maneuverability to cross and reach difficult lesions," Guidant says. The device also features P-Flex Plus, an extended balloon pressure material that "widens the variety of inflation choices." U.S. marketing will begin immediately...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.